okezone.com : Vaccine MVA-B, Able to Fight HIV

MADRID - Spanish research team has conducted a phase I clinical trials that demonstrate the use of new vaccines against Human react more Immunideficiency Virus (HIV).

The vaccine has proven capable of providing an immune response by 90 percent in HIV patients. Approximately 85 percent of the subjects who took the tests this study also showed the same response 12 months later.

The research team was named the Spanish Scientific Research Superior Council (CSIC), where experts from the Gregorio Maranon Hospital (Madrid) and Hospital Clinic (Barcelona) serves as principal investigator who creates a new therapeutic approach, and this clinical trial.

According to scientists, the HIV virus in the body is modified as new therapies are safe and efficient, especially in doing research on the subject. Results from a phase I clinical trials have been published in the journal Vaccine and Virology.

This vaccine is given the name of the MVA-B has been patented by the CSIC. This vaccine relies on the ability to boost the human immune system and immune system to respond effectively to all types of viruses.

Virus particles and infected cells are targets that are always targeted by the MVA-B, but the human body's defense needs time to attack both.

Softpedia quoted as saying on Thursday (29/09/2011), chief researcher of National Biotech CSIC Center (NBC), Mariano Esteban explains the MVA-B vaccine has been proven stronger than other vaccines that are currently being studied or even better.

MVA-B was first proved highly efficient against HIV in laboratory tests conducted on mice infected with HIV. Future studies analyzing the effectiveness of the vaccine against Simian immunodeficiency virus (SIV), a virus similar to HIV.

As the name implies MVA-B focused to fight the HIV virus to type B. The virus is most often spread across Europe. According to the research team, the safety of clinical trials is guaranteed by the fact that the HIV gene that carries a lower virus can not replicate themselves.

Phase I of clinical trials are done to 30 people and 24 people including dihasilakn immune response by the MVA-B, while the other six should be given a placebo (vaccine injections). Researchers observing the development of clinical trial subjects at weeks 1, 4 and 16, and studied thoroughly in the week to 48.

"Our body is full of lymphocytes, each of which is useful against different pathogens. The response to pathogens is needed, such as HIV type one which can not be defeated by nature," he explained.

At week 48, all patients in the control group CD4 + T lymphocytes and CD8 + that is the subject of this study experienced an increase in the immune system of 38.5 percent and 69.2 percent.

"If this genetic combination to get through clinical trials next stage, ie stage II and stage III and successfully respond to the human immune system. So in the future the possibility of HIV can be cured," he concluded.